Watanabe K, Hibino J, Ikemoto H
Jpn J Antibiot. 1982 Aug;35(8):1907-10.
Netilmicin, a new semisynthetic aminoglycoside antibiotic recently developed by Shering Co., was injected to 5 patients with respiratory tract infection (2 cases of diffuse panbronchiolitis, 2 cases of bronchiectasis and 1 case of bronchial asthma with infection). A daily dose of netilmicin was 200 mg by intramuscular injection and duration of netilmicin therapy was for 7 to 14 days. Clinical response to netilmicin therapy of respiratory tract infection was good in 3 cases, fair in 1 case and poor in 1 case. No subjective and objective findings considered as the side effect was observed and laboratory examinations showed no abnormality. It may be concluded from the above clinical results that netilmicin may be effective for respiratory tract infections and further study may prove its efficacy.
奈替米星是先灵公司最近研制的一种新型半合成氨基糖苷类抗生素，对5例呼吸道感染患者（2例弥漫性泛细支气管炎、2例支气管扩张症和1例伴有感染的支气管哮喘）进行了注射治疗。奈替米星的每日剂量为200毫克，通过肌肉注射给药，治疗持续时间为7至14天。奈替米星治疗呼吸道感染的临床反应，3例良好，1例尚可，1例较差。未观察到被视为副作用的主观和客观表现，实验室检查也未显示异常。从上述临床结果可以得出结论，奈替米星可能对呼吸道感染有效，进一步研究可能会证实其疗效。
